CDTX - Cidara Therapeutics adds 31% on mid-stage data of flu prophylactic drug
- Cidara Therapeutics ( NASDAQ: CDTX ) closed up 31% on Wednesday, boosted by positive interim results from a mid-stage trial on CD388, its prophylactic drug candidate for influenza.
- Results on healthy volunteers showed that CD388 decreased influenza viral replication in the upper respiratory tract and lowered influenza incidence rate in a human challenge model.
- Cidara has been on a tear since the beginning of the year. Including today's gain, it is up ~163% year to date.
- Seeking Alpha's Quant Rating v iews Cidara ( CDTX ) as a strong buy.
For further details see:
Cidara Therapeutics adds 31% on mid-stage data of flu prophylactic drug